In vitro study on anti-proliferative and anti-cancer activity of picrosides in triple-negative breast cancer
- PMID: 38717628
- DOI: 10.1007/s12032-024-02397-3
In vitro study on anti-proliferative and anti-cancer activity of picrosides in triple-negative breast cancer
Abstract
Picrorhiza kurroa, an "Indian gentian," a known Himalayan medicinal herb with rich source of phytochemicals like picrosides I, II, and other glycosides, has been traditionally used for the treatment of liver and respiratory ailments. Picrosides anti-proliferative, anti-oxidant, anti-inflammatory and other pharmacological properties were evaluated in treating triple-negative breast cancer (TNBC). Picroside I and II were procured from Sigma-Aldrich and were analyzed for anti-cancer activity in triple-negative breast cancer (MDA-MB-231) cells. Cell viability was analyzed using MTT and trypan blue assays. Apoptosis was analyzed through DNA fragmentation and Annexin V/PI flow cytometric analysis. Wound healing and cell survival assays were employed to determine the inhibition of invasion capacity and anti-proliferative activity of picrosides in MDA-MB-231 cells. Measurement of intracellular ROS was studied through mitochondrial membrane potential assessment using DiOC6 staining for anti-oxidant activity of picrosides in MDA-MB-231 cells. Both Picroside I and II have shown decreased cell viability of MDA-MB-231 cells with increasing concentrations. IC50 values of 95.3 µM and 130.8 µM have been obtained for Picroside I and II in MDA-MB-231 cells. Early apoptotic phase have shown an increase of 20% (p < 0.05) with increasing concentrations (0, 50, 75, and 100 µM) of Picroside I and 15% (p < 0.05) increase with Picroside II. Decrease in mitochondrial membrane potential of 2-2.5-fold (p < 0.05) was observed which indicated decreased reactive oxygen species (ROS) generation with increasing concentrations of Picroside I and II. An increasing percentage of 70-80% (p < 0.05) cell population was arrested in G0/G1 phase of cell cycle after Picroside I and II treatment in cancer cells. Our results suggest that Picroside I and II possess significant anti-proliferative and anti-cancer activity which is mediated by inhibition of cell growth, decreased mitochondrial membrane potential, DNA damage, apoptosis, and cell cycle arrest. Therefore, Picroside I and II can be developed as a potential anti-cancer drug of future and further mechanistic studies are underway to identify the mechanism of anti-cancer potential.
Keywords: Anti-cancer; Anti-proliferative; Apoptosis; DNA damage; Picrosides; ROS.
© 2024. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.
Similar articles
-
Chloroform Fraction of Methanolic Extract of Seeds of Annona muricata Induce S Phase Arrest and ROS Dependent Caspase Activated Mitochondria-Mediated Apoptosis in Triple-Negative Breast Cancer.Anticancer Agents Med Chem. 2021;21(10):1250-1265. doi: 10.2174/1871520620666200918101448. Anticancer Agents Med Chem. 2021. PMID: 32951586
-
Novel indole Schiff base β-diiminato compound as an anti-cancer agent against triple-negative breast cancer: In vitro anticancer activity evaluation and in vivo acute toxicity study.Bioorg Chem. 2024 Nov;152:107730. doi: 10.1016/j.bioorg.2024.107730. Epub 2024 Aug 16. Bioorg Chem. 2024. PMID: 39216194
-
Anti-Proliferative and Pro-Apoptotic Effects of Calligonum comosum (L'Her.) Methanolic Extract in Human Triple-Negative MDA-MB-231 Breast Cancer Cells.J Evid Based Integr Med. 2020 Jan-Dec;25:2515690X20978391. doi: 10.1177/2515690X20978391. J Evid Based Integr Med. 2020. PMID: 33302699 Free PMC article.
-
The beneficial pharmacological effects and potential mechanisms of picroside II: Evidence of its benefits from in vitro and in vivo.Biomed Pharmacother. 2020 Oct;130:110421. doi: 10.1016/j.biopha.2020.110421. Epub 2020 Jul 13. Biomed Pharmacother. 2020. PMID: 32674016 Review.
-
"Picrosides" from Picrorhiza kurroa as potential anti-carcinogenic agents.Biomed Pharmacother. 2019 Jan;109:1680-1687. doi: 10.1016/j.biopha.2018.11.048. Epub 2018 Nov 20. Biomed Pharmacother. 2019. PMID: 30551422 Review.
References
-
- Khan RI, Bui MM. A review of triple-negative breast cancer. Cancer Control. 2010;17:173–6. - DOI
-
- Zagami P, Carey LA. Triple negative breast cancer: pitfalls and progress. NPJ Breast Cancer. 2022;8:95. https://doi.org/10.1038/s41523-022-00468-0 . - DOI - PubMed - PMC
-
- Anders C, Carey LA. Understanding and treating triple negative breast cancer. Oncology. 2008;22:1233–43.
-
- Cleator S, Heller W, Coombes RC. Triple-negative breast cancer: therapeutic options. Lancet Oncol. 2007;8:235–44. https://doi.org/10.1016/S1470-2045(07)70074-8 . - DOI - PubMed
-
- Ivanova M, Porta FM, Giugliano F, Frascarelli C, Sajjadi E, Venetis K, Cursano G, Mazzarol G, Guerini-Rocco E, Curigliano G, Criscitiello C, Fusco N. Breast cancer with brain metastasis: molecular insights and clinical management. Genes (Basel). 2023;14:1160. https://doi.org/10.3390/genes14061160 . - DOI - PubMed
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Research Materials
Miscellaneous